Pharming Group N.V annual diluted eps
Diluted EPSBasic EPS
2019
2020
2021
2022
2023
2024
2025
Pharming Group N.V EPS History: Annual & Quarterly (PHAR)
Pharming Group N.V's diluted EPS was $0.00 for fiscal 2025.
View full Pharming Group N.V company overviewPharming Group N.V annual diluted eps history
| Fiscal year | Period ended | Diluted EPS | Basic EPS | Change | Growth |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $0.00 | $0.00 | $0.02 | — |
| 2024 | 2024-12-31 | -$0.02 | -$0.02 | -$0.00 | — |
| 2023 | 2023-12-31 | -$0.02 | -$0.02 | -$0.04 | — |
| 2022 | 2022-12-31 | $0.02 | $0.02 | -$0.00 | −17.39% |
| 2021 | 2021-12-31 | $0.02 | $0.03 | -$0.03 | −58.18% |
| 2020 | 2020-12-31 | $0.06 | $0.06 | -$0.00 | −8.33% |
| 2019 | 2019-12-31 | $0.06 | $0.07 | — | — |
Pharming Group N.V quarterly diluted eps
Diluted EPSBasic EPS
Q4.24
Q1.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | Diluted EPS | Basic EPS | Change | YoY change |
|---|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | -$0.07 | -$0.07 | $0.15 | — |
| Q4 2025 | 2025-12-31 | $0.07 | $0.08 | $0.03 | +75.00% |
| Q1 2025 | 2025-03-31 | -$0.22 | -$0.22 | — | — |
| Q4 2024 | 2024-12-31 | $0.04 | $0.04 | — | — |
Pharming Group N.V diluted eps trends
Over the last five fiscal years, Pharming Group N.V's diluted eps decreased from $0.06 to $0.00, a change of -$0.05. The latest reported quarter, Q1 2026, shows -$0.07.
About the metric
What earnings per share (EPS) means
Earnings per share (EPS) shows how much profit or loss is attributable to each common share. Diluted EPS includes the potential effect of convertible securities, options, and other instruments that could increase the share count, while basic EPS uses the weighted-average common shares actually outstanding.
Calculation and source
SEC-reported diluted and basic EPS
TickerStat displays diluted and basic earnings per share from SEC filings. Historical EPS values are adjusted to the current share basis when SEC-reported stock-split conversion ratios are available; they are not analyst estimates or earnings forecasts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharming Group N.V source filings ↗Community posts
Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients ...